Eli Lilly to Pay $24 Million in Zyprexa Off-Label Marketing Suit


The AP reports, “Utah has agreed to a $24 million settlement with Eli Lilly & Co. over claims the drugmaker engaged in off-label marketing of the anti-psychotic drug Zyprexa [olanzapine],” according to Attorney General Mark Shurtleff. The drug is currently “approved for the treatment of schizophrenia and certain types of bipolar disorder,” but “the company’s sales force illegally promoted Zyprexa for uses not approved by the” FDA, including “dementia, Alzheimer’s, agitation, and depression,” he added.

Please see full article below for more inforamtion.

LOADING PDF: If there are any problems, click here to download the file.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Robert Kraft, Kraft & Associates | Attorney Advertising

Written by:


Kraft & Associates on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:

Sign up to create your digest using LinkedIn*

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.

Already signed up? Log in here

*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.